NovoCure Limited (NVCR)
(Delayed Data from NSDQ)
$12.05 USD
-0.41 (-3.29%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $12.02 -0.03 (-0.25%) 5:38 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
NVCR 12.05 -0.41(-3.29%)
Will NVCR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NVCR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVCR
NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade
NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock?
NVCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect?
NovoCure (NVCR) Reports Q4 Loss, Tops Revenue Estimates
Strength Seen in NovoCure (NVCR): Can Its 16.8% Jump Turn into More Strength?
Other News for NVCR
Commit To Buy NovoCure At $7.50, Earn 15.3% Using Options
Buy Rating on NovoCure: Promising METIS Therapy and Strategic Commercial Execution
Novocure price target raised by $3 at Piper Sandler, here's why
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
Novocure announces 20 presentations at AACR 2024